ETBX 061

Drug Profile

ETBX 061

Alternative Names: Ad5 MUC1; Adenoviral MUC1 vaccine - Etubics; ETBX-061

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Etubics Corporation
  • Developer NantKwest; National Cancer Institute (USA)
  • Class Antineoplastics; Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer; Colorectal cancer
  • Phase I Prostate cancer; Solid tumours

Most Recent Events

  • 02 Jul 2018 NantKwest plans the QUILT-2.024 phase II trial for Non Small Cell Lung Cancer (Late-stage disease) in USA , (NCT03574649)
  • 29 Jun 2018 Phase-I/II clinical trials in Colorectal cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (SC) (NCT03563157)
  • 20 Jun 2018 NantKwest plans the QUILT-3.088 phase II trial for Pancreatic Cancer (Metastatic disease) in USA , (NCT03563144)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top